Pharma

Organon Signs a Licensing Deal with Henlius for Biosimilars Targeting Osteoporosis and Breast Cancer

Global women’s health pharma company Organon has entered into an agreement with Shanghai Henlius Biotech, whereby Organon will license commercialization rights for biosimilar candidates referencing Perjeta (pertuzumab, HLX11) and Prolia/Xgeva (denosumab, HLX14). Organon will acquire exclusive global commercialization rights except for China; including Hong Kong, Macau and Taiwan. Pertuzumab is used for the treatment of certain patients with HER2+ breast cancer in combinations with…

Carlyle and PAI Partners Agree to Acquire Women’s Health Pharma Company Theramex

Global investment firms PAI Partners and Carlyle have agreed to acquire Theramex, a global specialty pharmaceuticals company focused on women’s health, from CVC Capital Partners VI. The details Theramex was created following the carve-out of a portfolio of women’s health pharma products in 2018, and has subsequently developed into one of the largest specialty pharma platforms dedicated to women and their health.…

Women’s Health Pharma Company ObsEva Sells Regional Rights to Its Uterine Fibroid Drug Linzagolix to Theramex

Women’s health pharma company Theramex and ObsEva, a biopharma company developing and commercializing novel therapies for women’s health have entered into a licensing agreement to commercialize and launch Linzagolix, an oral GnRH antagonist. The launch will be for global markets outside of the U.S., Canada, and Asia. Linzagolix is a GnRH receptor antagonist for the treatment of uterine fibroids. Linzagolix is also…

Ferring Invests in Fertility Platform Robyn with the Option to Acquire the Company

Pharma giant Ferring has finalized a two-year investment agreement including an acquisition option with Robyn, a community-driven fertility platform, that provides access to a network of integrative parental wellness tools, resources, and specialists. Robyn was founded in 2019 by Allison Kasirer and took part in the 2021 cohort of the UnitedHealthcare Accelerator Powered by Techstars. Prior to Ferring’s investment the company raised $1.2M…

Ferring Introduces a New Grant Program to Tackle Gender, Health and Racial Inequalities

Forensic analysis of stone age human fertility to better understand why modern-day sperm counts are falling, and a project to support safe birth in rural Ethiopia by providing trained midwives and solar power kits, are among 17 winners of a new Ferring Pharmaceuticals grant program. The new program is designed to tackle inequalities and disparities in reproductive medicine and maternal health, reinforcing…

Theramex Enters the OTC Market with Femarelle, a Non-hormonal Option to Treat Menopause Symptoms

Theramex, a company dedicated women’s health, recently acquired the Femarelle product licence to treat menopause symptoms. Femarelle will be available in different markets starting in late spring 2022. This commercialisation agreement was reached with Se-cure Pharmaceuticals, the company that developed the product. Femarelle offers non-hormonal therapy to balance oestrogen levels in women from peri-menopause through menopause to post-menopause relieving the symptoms and…

Organon Announces Plans to Acquire Forendo Pharma, a Biotech Company Targeting Endometriosis and PCOS

Organon and Forendo Pharma today announced that the companies have entered into a definitive agreement, under which Organon will acquire Forendo, a clinical-stage drug development company focused on novel treatments in women’s health. Forendo is pioneering the science of intracrinology, addressing disease through a novel, tissue-specific approach. Its lead clinical compound is an investigational, potentially first-in-class oral 17β-hydroxysteroid dehydrogenase type 1 (HSD17B1)…

Antiva Biosciences Raises a $31M Series D to Take its HPV Drug into Clinical Trials

Antiva Biosciences, a biopharmaceutical company developing novel, topical therapeutics for the treatment of pre-cancerous lesions caused by human papilloma virus (HPV) infection, has announced the closing of a $31M Series D. The financing was supported by a syndicate of life science investors led by Adjuvant Capital, a leading global and women’s health venture firm, and joined by GV, formerly Google Ventures. Participants in the financing…